SCHEMBL5264334

SCHEMBL5264334

CCC(=O)N(C)O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3357906 0.78
SCHEMBL8187320 0.77 ALDH1A1 (0.36)
SCHEMBL9640 0.76
SCHEMBL21765845 0.76 ALDH1A1 (0.41)
SCHEMBL3283077 0.76 ALOX5 (0.45)
SCHEMBL11413136 0.76 ALDH1A1 (0.41)
SCHEMBL4153230 0.76
SCHEMBL7603049 0.75
Hydrochloric Acid SCHEMBL5739091 0.73
Hydrochloric Acid SCHEMBL3021324 0.73

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1789388-A2 METHODS OF TREATMENT OF AMYLOIDOSIS USING SUBSTITUTED ETHANOLCYCLICAMINE ASPARTYL PROTEASE INHIBITORS Elan Pharmaceuticals, Inc. (US) 2007-05-30 EP claimed
WO-2006026532-A2 METHODS OF TREATMENT OF AMYLOIDOSIS USING SUBSTITUTED ETHANOLCYCLICAMINE ASPARTYL PROTEASE INHIBITORS ELAN PHARMACEUTICALS, INC. (US) 2006-03-09 WO claimed
EP-0559677-B1 HYDROXAMIC ACIDS FOR PREVENTING REPERFUSION INJURY BRITISH TECH GROUP (GB) 1996-09-11 EP claimed
US-5506266-A CONTROLS FREE RADICAL INDUCED DAMAGE ARISING FROM MYOCARDIAL INFRACTION OR STROKE, PERTICULARYL HEART DAMAGE BRITISH TECHNOLOGY GROUP LIMITED (GB) 1996-04-09 US claimed
EP-0559677-A1 HYDROXAMIC ACIDS FOR PREVENTING REPERFUSION INJURY. BRITISH TECH GROUP (GB) 1993-09-15 EP claimed
WO-1992008453-A1 HYDROXAMIC ACIDS FOR PREVENTING REPERFUSION INJURY BRITISH TECHNOLOGY GROUP LTD (GB) 1992-05-29 WO claimed
WO-2016086169-A1 BILE ACID ANALOGS AS FXR/TGR5 AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. (US) 2016-06-02 WO disclosed
US-9309260-B2 Inhibitors of hepatitis C virus PRESIDIO PHARMACEUTICALS, INC. (US) 2016-04-12 US disclosed
CN-103435511-A Synthetic method for N, N-disubstituted-2-hydroxyl aliphatic amide compound ZHEJIANG JIANGSHAN CHEMICAL CO LTD 2013-12-11 CN disclosed
US-20120276051-A1 INHIBITORS OF HEPATITIS C VIRUS PRESIDIO PHARMACEUTICALS, INC. (US) 2012-11-01 US disclosed
US-20120251497-A1 INHIBITORS OF HEPATITIS C VIRUS PRESIDIO PHARMACEUTICALS, INC. 2012-10-04 US disclosed
US-8002120-B2 Modified polyamide membrane DOW GLOBAL TECHNOLOGIES LLC (US) 2011-08-23 US disclosed
US-20110120942-A1 MODIFIED POLYAMIDE MEMBRANE THE DOW CHEMICAL COMPANY 2011-05-26 US disclosed
EP-0586229-A1 3-Hydroxy-3-(subst-akyl)-pyrrolidines as 5-lipoxygenase inhibitors ZENECA LIMITED (GB) 1994-03-09 EP disclosed
EP-0196184-B1 ARYL DERIVATIVES THE WELLCOME FOUNDATION LIMITED (GB) 1992-09-16 EP disclosed
US-5112848-A Antiasthmatics and antiarthritic agents ABBOTT LABORATORIES (US) 1992-05-12 US disclosed
EP-0200377-B1 HYDROXAMATES SQUIBB & SONS INC (US) 1991-10-09 EP disclosed
EP-0320628-A1 Substituted furan compounds which are useful in inhibiting lipoxygenase enzymes, particularly 5-lipoxygenase ABBOTT LABORATORIES (US) 1989-06-21 EP disclosed
EP-0200377-A2 Hydroxamates E.R. Squibb &amp; Sons, Inc. (US) 1986-11-05 EP disclosed
US-4604407-A Hydroxamates E. R. SQUIBB & SONS, INC. (US) 1986-08-05 US disclosed